Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation

被引:225
|
作者
Sureda, Anna
Robinson, Stephen
Canals, Carmen
Carella, Angela M.
Boogaerts, Marc A.
Caballero, Dolores
Hunter, Ann E.
Kanz, Lothar
Slavin, Shimon
Cornelisson, Jan J.
Gramatzki, Martin
Niederwieser, Dietger
Russell, Nigel H.
Schmitz, Norbert
机构
[1] Clinical Hematology Division, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Antoni Maria i Claret
关键词
D O I
10.1200/JCO.2007.13.2415
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival ( OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT). Patients and Methods A total of 168 patients with HL undergoing a first alloSCT ( RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed. Results NRM was significantly decreased in the RIC group ( hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P =.001). OS was better in the RIC group ( HR, 2.05; 95% CI, 1.27 to 3.29; P =.04) and there was a trend for better PFS in the RIC group ( HR, 1.53; 95% CI, 0.97 to 2.40; P =.07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS. Conclusion The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 50 条
  • [1] Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Genadieva-Stavrik, S.
    Boumendil, A.
    Dreger, P.
    Peggs, K.
    Briones, J.
    Corradini, P.
    Bacigalupo, A.
    Socie, G.
    Bonifazi, F.
    Finel, H.
    Velardi, A.
    Potter, M.
    Bruno, B.
    Castagna, L.
    Malladi, R.
    Russell, N.
    Sureda, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (12) : 2251 - 2257
  • [2] Allogeneic peripheral blood stem cell transplantation after reduced-intensity conditioning in refractory or relapsed Hodgkin lymphoma
    Alvarez, I
    Sureda, A
    Caballero, D
    Urbano, A
    Ribera, J
    Canales, M
    Hernández-Boluda, J
    Arranz, R
    Bernal, T
    de la Serna, J
    Diez, JL
    Moraleda, J
    Rubio-Félix, D
    Sierra, J
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S13 - S14
  • [3] Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin's Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Stavrik, Sonja G. Genadieva
    Boumendil, Arlene
    Thomson, Kirsty
    Briones, Javier
    Corradini, Paolo
    Bacigalupo, Andrea
    Socie, Gerard
    Bandini, Guiseppe
    Finel, Herve
    Velardi, Andrea
    Potter, Michael
    Benedetto, Bruno
    Castagna, Luca
    Craddock, Charles
    Russell, Nigel
    Dreger, Peter
    Anna, Sureda
    [J]. BLOOD, 2014, 124 (21)
  • [4] Gemcitabine, Fludarabine; and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
    Anderlini, Paolo
    Saliba, Rima M.
    Ledesma, Celina
    Plair, Tamera
    Alousi, Amin M.
    Hosing, Chitra M.
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday R.
    Shpall, Elizabeth J.
    Fanale, Michelle A.
    Hagemeister, Frederick B.
    Oki, Yasuhiro
    Neelapu, Saatva
    Romaguera, Jorge E.
    Younes, Anas
    Champlin, Richard E.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) : 1333 - 1337
  • [5] Reduced-intensity conditioning allogeneic stem cell transplantation for patients with refractory or relapsed non-Hodgkin lymphoma
    De Lavallade, H.
    Bouabdallah, R.
    Faucher, C.
    Furst, S.
    El Cheikh, J.
    Vey, N.
    Stoppa, A. M.
    Sainty, D.
    Arnoulet, C.
    Xerri, L.
    Cassier, P.
    Gastaut, J. A.
    Blaise, D.
    Mohty, M.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S149 - S149
  • [6] Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era
    Anderlini, Paolo
    Saliba, Rima
    Ledesma, Celina
    Chancoco, Christina M.
    Alexander, Tamera R.
    Alousi, Amin M.
    Hosing, Chitra
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday R.
    Shpall, Elizabeth J.
    Fanale, Michelle A.
    Oki, Yasuhiro
    Romaguera, Jorge E.
    Neelapu, Sattva S.
    Younes, Anas
    Champlin, Richard E.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S72 - S72
  • [7] Allogeneic stem cell transplantation with reduced-intensity conditioning in patients with relapsed lymphoma
    Rivas, M.
    Berro, M.
    Belaustegui, S.
    Prates, V.
    Yantorno, S.
    Milone, J.
    Remaggi, G.
    Rolon, J. Martinez
    Milone, G.
    Basquiera, A.
    Garcia, J.
    Sturich, G.
    Kusminsky, G.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 : S257 - S258
  • [8] Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: an update from the Lymphoma Working Party of the EBMT
    Robinson, S
    Taghipour, G
    Canals, C
    Russell, N
    Beguin, Y
    Zander, A
    Jouet, J
    Goldstone, A
    Sureda, A
    Schmitz, N
    [J]. BONE MARROW TRANSPLANTATION, 2006, 37 : S25 - S26
  • [9] Allogeneic stem cell transplantation after a reduced-intensity conditioning regimen vs conventional allogeneic stem cell transplantation in Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation
    Sureda, A
    Robinson, S
    de Elvira, CR
    Taghipour, G
    Carella, A
    Mackinnon, S
    Oogaerts, M
    Caballero, D
    Michallet, M
    Russell, N
    Schmitz, N
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 : S5 - S6
  • [10] Reduced-intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin and non-Hodgkin lymphoma.
    Lerner, D
    Azevedo, AM
    Colares, M
    de Cássia, R
    Tavares, B
    Maradei, SC
    Lima, J
    Lobo, AMG
    Tabak, DG
    Urago, K
    Lima, MC
    Maiolino, A
    Bouzas, LFS
    [J]. BLOOD, 2005, 106 (11) : 443B - 443B